Drug Recall: ProSirona Homeopathic Calendula Oil Manufacturing Deviations
ProSirona Homeopathic Calendula Oil (Lot B-02) is being recalled because the manufacturer failed to follow Current Good Manufacturing Practice standards. The voluntary recall affects products distributed nationwide and in Australia.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II voluntary precautionary recall due to manufacturing practice deviations with no reported illnesses or injuries. Per the severity rubric, manufacturing compliance issues without specific confirmed hazards or health impacts are classified as Moderate.
Plain-English summary
ProSirona, a homeopathic formula calendula oil packaged in 1/8 fl. oz. bottles, is the subject of this FDA recall. The product was distributed nationwide and to Australia under Lot Code B-02, with 72 bottles recalled.
The recall was initiated due to Current Good Manufacturing Practice (cGMP) deviations—violations of FDA manufacturing standards. This voluntary recall was initiated by the recalling firm, Atlantic Management Resources Ltd., on December 12, 2022, and was terminated on September 20, 2023.
Consumers who have purchased this product should discontinue use immediately. No illnesses or injuries have been reported in connection with this recall. For more information or to report any adverse events, consumers may contact the FDA or the recalling firm.
The recalled product
- Product
- ProSirona, A Homeopathic Formula, Calendula Oil packaged in 1/8 Fl. oz. (3.5 g) bottles, Dist. by: Endometriosis Assoc. Inc. (International), Mfg. by Claire Ellen Topicals, P.O. Box 901 Westborough, MA 01581, USA, NDC# 66233-712-01.
- Manufacturer
- Atlantic Management Resources Ltd.
- Category
- Drug — Homeopathic / Topical
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot Code B-02
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27